I期临床-话题@MedSci

#I期临床#

570篇内容 | 7031人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1653104, encodeId=3186165310474, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=单抗III期临床试验失败案例及原因分析, objectType=article, longId=201985, objectId=5e8f20198506, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e8f20198506, replyNumber=0, likeNumber=0, createdTime=2021-07-11, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e8f20198506, moduleTitle=单抗III期临床试验失败案例及原因分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e8f20198506)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653093, encodeId=dae11653093da, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验, objectType=article, longId=201324, objectId=3539201324d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3539201324d6, replyNumber=0, likeNumber=61, createdTime=2021-04-15, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3539201324d6, moduleTitle=Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3539201324d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653047, encodeId=19c2165304ef8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Gastroenterology：Upadacitinib治疗中重度克罗恩病II期临床获得成功, objectType=article, longId=196772, objectId=914c196e721f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=914c196e721f, replyNumber=0, likeNumber=70, createdTime=2020-07-16, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=914c196e721f, moduleTitle=Gastroenterology：Upadacitinib治疗中重度克罗恩病II期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=914c196e721f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653091, encodeId=b2e3165309121, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率, objectType=article, longId=201182, objectId=099320118291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=099320118291, replyNumber=0, likeNumber=82, createdTime=2021-06-11, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=099320118291, moduleTitle=Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=099320118291)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653127, encodeId=92a6165312e52, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=信达生物公布信迪利单抗联合贝伐珠单抗一线治疗肝癌III期临床研究结果, objectType=article, longId=203674, objectId=94d42036e4b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94d42036e4b2, replyNumber=0, likeNumber=79, createdTime=2021-05-26, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94d42036e4b2, moduleTitle=信达生物公布信迪利单抗联合贝伐珠单抗一线治疗肝癌III期临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94d42036e4b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653148, encodeId=f16516531488c, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Gastroenterology：工程化FGF-19类似物Aldafermin治疗NSAH II期临床获得成功, objectType=article, longId=205638, objectId=cd2320563849, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd2320563849, replyNumber=0, likeNumber=80, createdTime=2021-02-08, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd2320563849, moduleTitle=Gastroenterology：工程化FGF-19类似物Aldafermin治疗NSAH II期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd2320563849)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653145, encodeId=31c71653145e8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Falkieri治疗双相抑郁症：II期临床取得了阳性结果, objectType=article, longId=205566, objectId=fd1d2055667a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd1d2055667a, replyNumber=0, likeNumber=98, createdTime=2021-10-12, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd1d2055667a, moduleTitle=Falkieri治疗双相抑郁症：II期临床取得了阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd1d2055667a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653166, encodeId=f43016531669d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Inovio宣布DNA免疫疗法治疗宫颈癌变创新药III期临床成功, objectType=article, longId=208135, objectId=11df20813559, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11df20813559, replyNumber=0, likeNumber=91, createdTime=2021-10-10, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11df20813559, moduleTitle=Inovio宣布DNA免疫疗法治疗宫颈癌变创新药III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11df20813559)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653051, encodeId=33af1653051e6, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=ANG-3777治疗COVID-19急性肺损伤：已启动II期临床试验, objectType=article, longId=197270, objectId=3bb219e27057, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bb219e27057, replyNumber=0, likeNumber=76, createdTime=2020-11-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bb219e27057, moduleTitle=ANG-3777治疗COVID-19急性肺损伤：已启动II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3bb219e27057)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653111, encodeId=f98c1653111e0, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=GC4419治疗晚期胰腺癌的I/II期临床试验：已取得阳性数据, objectType=article, longId=202473, objectId=2a172024e33a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a172024e33a, replyNumber=0, likeNumber=99, createdTime=2021-03-29, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a172024e33a, moduleTitle=GC4419治疗晚期胰腺癌的I/II期临床试验：已取得阳性数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a172024e33a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653175, encodeId=11b016531e575, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=康泰生物灭活新冠疫苗（KCONVAC）I/II期临床试验数据显示出优异的安全性和免疫原性, objectType=article, longId=209884, objectId=8e3c20988469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e3c20988469, replyNumber=0, likeNumber=21, createdTime=2021-07-07, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e3c20988469, moduleTitle=康泰生物灭活新冠疫苗（KCONVAC）I/II期临床试验数据显示出优异的安全性和免疫原性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e3c20988469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653151, encodeId=9eb4165315171, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=一种治疗耐甲氧西林的金黄色葡萄球菌（MRSA）感染的新型药物ALS-4：即将开展I期临床, objectType=article, longId=205973, objectId=25542059e345, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25542059e345, replyNumber=0, likeNumber=88, createdTime=2021-06-22, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25542059e345, moduleTitle=一种治疗耐甲氧西林的金黄色葡萄球菌（MRSA）感染的新型药物ALS-4：即将开展I期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25542059e345)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653128, encodeId=1645165312801, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=多激酶抑制剂ON 123300治疗复发/难治性晚期癌症：即将开展I期临床研究, objectType=article, longId=203706, objectId=f94a203e06d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f94a203e06d6, replyNumber=0, likeNumber=0, createdTime=2020-11-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f94a203e06d6, moduleTitle=多激酶抑制剂ON 123300治疗复发/难治性晚期癌症：即将开展I期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f94a203e06d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653053, encodeId=a1ba1653053bf, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=靶向Aβ的阿尔茨海默症新药BAN2401，开始III期临床研究, objectType=article, longId=197608, objectId=a82f19e608e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a82f19e608e8, replyNumber=0, likeNumber=90, createdTime=2021-02-04, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a82f19e608e8, moduleTitle=靶向Aβ的阿尔茨海默症新药BAN2401，开始III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a82f19e608e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653072, encodeId=98fe16530e253, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=MS1819联合PERT治疗胰腺功能不全的囊性纤维化：II期临床取得积极进展, objectType=article, longId=199301, objectId=8caa199301e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8caa199301e8, replyNumber=0, likeNumber=59, createdTime=2021-01-30, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8caa199301e8, moduleTitle=MS1819联合PERT治疗胰腺功能不全的囊性纤维化：II期临床取得积极进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8caa199301e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653147, encodeId=067e165314e29, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=DB102（Enzastaurin）治疗初治胶质母细胞瘤（GBM）：已启动III期临床试验, objectType=article, longId=205630, objectId=ad3c205630c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad3c205630c9, replyNumber=0, likeNumber=70, createdTime=2021-03-25, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad3c205630c9, moduleTitle=DB102（Enzastaurin）治疗初治胶质母细胞瘤（GBM）：已启动III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad3c205630c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653123, encodeId=72fd1653123c6, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=FDA批准候选药物lanifibranor进入III期临床，以治疗非酒精性脂肪性肝炎（NASH）, objectType=article, longId=203274, objectId=cfcb2032e4c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfcb2032e4c1, replyNumber=0, likeNumber=72, createdTime=2021-05-19, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfcb2032e4c1, moduleTitle=FDA批准候选药物lanifibranor进入III期临床，以治疗非酒精性脂肪性肝炎（NASH）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfcb2032e4c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653099, encodeId=c332165309954, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=CAR-T细胞疗法MB-102治疗BPDCN、AML、hrMDS：即将开展多中心I/II期临床试验, objectType=article, longId=201543, objectId=a72820154315, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a72820154315, replyNumber=0, likeNumber=95, createdTime=2021-05-30, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a72820154315, moduleTitle=CAR-T细胞疗法MB-102治疗BPDCN、AML、hrMDS：即将开展多中心I/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a72820154315)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653159, encodeId=4d0616531591f, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=ASCO GU 2021：ERLEADA联合ZYTIGA治疗转移性去势抵抗性前列腺癌III期临床, objectType=article, longId=207001, objectId=7c4620e00147, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c4620e00147, replyNumber=0, likeNumber=75, createdTime=2021-05-14, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c4620e00147, moduleTitle=ASCO GU 2021：ERLEADA联合ZYTIGA治疗转移性去势抵抗性前列腺癌III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c4620e00147)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653037, encodeId=e2e9165303e8a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=默克的PD-1单抗Keytruda联合化疗用于晚期尿路上皮癌，III期临床失败, objectType=article, longId=195619, objectId=fa0e195619b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa0e195619b6, replyNumber=0, likeNumber=68, createdTime=2020-10-15, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa0e195619b6, moduleTitle=默克的PD-1单抗Keytruda联合化疗用于晚期尿路上皮癌，III期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa0e195619b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

智慧医人 (审核中...)

前往app查看评论内容

#I期临床#

单抗III期临床试验失败案例及原因分析

2021-07-11

hb2008ye (审核中...)

前往app查看评论内容

#I期临床#

Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验

2021-04-15

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Gastroenterology：Upadacitinib治疗中重度克罗恩病II期临床获得成功

2020-07-16

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率

2021-06-11

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

信达生物公布信迪利单抗联合贝伐珠单抗一线治疗肝癌III期临床研究结果

2021-05-26

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Gastroenterology：工程化FGF-19类似物Aldafermin治疗NSAH II期临床获得成功

2021-02-08

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Falkieri治疗双相抑郁症：II期临床取得了阳性结果

2021-10-12

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Inovio宣布DNA免疫疗法治疗宫颈癌变创新药III期临床成功

2021-10-10

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

ANG-3777治疗COVID-19急性肺损伤：已启动II期临床试验

2020-11-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

GC4419治疗晚期胰腺癌的I/II期临床试验：已取得阳性数据

2021-03-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

康泰生物灭活新冠疫苗（KCONVAC）I/II期临床试验数据显示出优异的安全性和免疫原性

2021-07-07

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

一种治疗耐甲氧西林的金黄色葡萄球菌（MRSA）感染的新型药物ALS-4：即将开展I期临床

2021-06-22

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

多激酶抑制剂ON 123300治疗复发/难治性晚期癌症：即将开展I期临床研究

2020-11-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

靶向Aβ的阿尔茨海默症新药BAN2401，开始III期临床研究

2021-02-04

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

MS1819联合PERT治疗胰腺功能不全的囊性纤维化：II期临床取得积极进展

2021-01-30

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

DB102（Enzastaurin）治疗初治胶质母细胞瘤（GBM）：已启动III期临床试验

2021-03-25

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

FDA批准候选药物lanifibranor进入III期临床，以治疗非酒精性脂肪性肝炎（NASH）

2021-05-19

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

CAR-T细胞疗法MB-102治疗BPDCN、AML、hrMDS：即将开展多中心I/II期临床试验

2021-05-30

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

ASCO GU 2021：ERLEADA联合ZYTIGA治疗转移性去势抵抗性前列腺癌III期临床

2021-05-14

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

默克的PD-1单抗Keytruda联合化疗用于晚期尿路上皮癌，III期临床失败

2020-10-15

科室
- - 订阅+
  - 更多科室
工具
服务